Cencora (COR) Stock Price & Analysis
COR Stock Chart & Stats
- Day’s Range
- MXN 5,350.75 - MXN 5,355.00
- 52-Week Range
- MXN 4,434.00 - MXN 6,940.20
- Previous Close
- MXN 5,350.75
- Volume
- 120
- Average Volume (3M)
- 0
- Market Cap
- MXN 1.19T
- Enterprise Value
- MXN 63.93B
- Total Cash (Recent Filing)
- MXN 2.82B
- Total Debt (Recent Filing)
- MXN 11.72B
- Price to Earnings (P/E)
- 24.5
- Beta
- 0.25
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- 86.09
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.76%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Cencora’s substantial free cash flow provides recurring internal funding for debt service, reinvestment, acquisitions, and shareholder returns. The absolute cash generation improves financial resilience and gives management flexibility to support growth initiatives without relying entirely on external financing.
Specialty-driven Operating Growth
Specialty pharmaceuticals, oncology services, and related healthcare solutions are producing stronger growth and operating leverage than the underlying distribution model alone. This mix shift can support earnings durability by expanding higher-value services and deepening relationships with providers and manufacturers.
Expansion In Community Oncology
The AON transaction would broaden Cencora’s oncology platform, add access to more physician practices, and strengthen its integrated support model in community cancer care. Management expects the acquisition to be adjusted-EPS accretive in the second year, indicating a potentially durable strategic growth contribution.
Bears Say
Elevated Leverage
High leverage relative to equity leaves Cencora more sensitive to working-capital movements, financing costs, and execution setbacks. Although equity has rebuilt and cash flow is strong, the historical negative equity and elevated debt burden reduce flexibility for future acquisitions or an operating downturn.
Structurally Thin Margins
Cencora’s distribution-heavy model operates with limited margin protection, so modest pricing, volume, or product-mix pressure can materially affect earnings. Thin profitability constrains resilience and makes sustained operating improvement important for absorbing cost inflation, customer changes, or manufacturer economics.
Manufacturer Pricing Pressure
Large manufacturer price reductions can suppress reported revenue and challenge the economics of pharmaceutical distribution, particularly when the business earns relatively thin margins. Continued pricing actions could make growth harder to convert into profit and increase reliance on specialty mix and operating execution.
Cencora News
COR FAQ
What was Cencora’s price range in the past 12 months?
What is Cencora’s market cap?
When is Cencora’s upcoming earnings report date?
How were Cencora’s earnings last quarter?
Is Cencora overvalued?
Does Cencora pay dividends?
What is Cencora’s EPS estimate?
How many shares outstanding does Cencora have?
What happened to Cencora’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cencora?
What is the TipRanks Smart Score and how is it calculated?
Cencora Stock Smart Score
Company Description
Cencora
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Robert Mauch
- Employees
- 49,000
- Website
- www.cencora.com
- Address
- 1 West First Avenue, Conshohocken, PA, 19428-1800, US
Cencora (COR) Earnings & Revenues
COR Company Deck
COR Earnings Call
Earnings Call SentimentPositive
The call emphasized strong execution and durable specialty-driven growth: consolidated revenue and adjusted gross profit growth, margin expansion, double-digit operating income increases, 12% EPS growth, upgraded EPS guidance, significant share repurchases, and robust free cash flow. Key drivers included strong U.S. Healthcare Solutions performance (MSOs and specialty), International momentum, and OneOncology outperforming expectations. Headwinds discussed were notable but largely manageable: $2.4B of manufacturer list-price reductions, a prior oncology customer loss, lower mail-order sales, acquisition-related higher operating expenses and increased interest expense, and a potential FY27 earnings headwind from the planned MWI transaction. Overall, the positive operational and financial outcomes and guidance raise outweigh the discrete and partly acquisition-related challenges.
View all MX:COR earnings summariesCOR Net sales Breakdown
- 90.55% U.S. Healthcare Solutions
- 9.45% International Healthcare Solutions
- -0.00% Intersegment eliminations
COR Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 2 | 7 |
| Technical Analysis | 5 | 1 | 1 |
| Moving Averages | 5 | 1 | 6 |
